 Raj Shah
Concepts (303)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cholangiopancreatography, Endoscopic Retrograde | 43 | 2022 | 180 | 10.000 |
Why?
| | Endoscopy, Digestive System | 20 | 2021 | 110 | 6.570 |
Why?
| | Pancreatic Ducts | 19 | 2022 | 69 | 6.160 |
Why?
| | Pancreatic Diseases | 13 | 2022 | 63 | 4.340 |
Why?
| | Calculi | 8 | 2022 | 16 | 4.220 |
Why?
| | Pancreatitis, Chronic | 11 | 2023 | 39 | 4.040 |
Why?
| | Bile Duct Neoplasms | 13 | 2021 | 56 | 3.980 |
Why?
| | Endosonography | 23 | 2023 | 132 | 3.370 |
Why?
| | Lithotripsy | 10 | 2022 | 40 | 3.270 |
Why?
| | Stents | 17 | 2023 | 466 | 3.080 |
Why?
| | Cholangitis, Sclerosing | 8 | 2022 | 66 | 3.030 |
Why?
| | Cholangiocarcinoma | 7 | 2021 | 38 | 2.860 |
Why?
| | Pancreatic Neoplasms | 17 | 2023 | 721 | 2.820 |
Why?
| | Bile Ducts, Intrahepatic | 5 | 2021 | 48 | 2.090 |
Why?
| | Drainage | 9 | 2023 | 145 | 2.000 |
Why?
| | Bile Ducts | 9 | 2019 | 68 | 1.940 |
Why?
| | Biliary Tract Surgical Procedures | 4 | 2021 | 21 | 1.930 |
Why?
| | Endoscopy, Gastrointestinal | 11 | 2023 | 201 | 1.840 |
Why?
| | Constriction, Pathologic | 15 | 2022 | 207 | 1.780 |
Why?
| | Gallstones | 4 | 2018 | 28 | 1.380 |
Why?
| | Pancreas | 6 | 2021 | 276 | 1.330 |
Why?
| | Microscopy, Confocal | 8 | 2021 | 304 | 1.320 |
Why?
| | Biliary Tract Diseases | 4 | 2016 | 32 | 1.280 |
Why?
| | Carcinoma, Pancreatic Ductal | 5 | 2016 | 209 | 1.150 |
Why?
| | Endoscopes | 3 | 2017 | 18 | 1.140 |
Why?
| | Pancreatic Pseudocyst | 4 | 2018 | 13 | 1.140 |
Why?
| | Cholestasis | 6 | 2021 | 225 | 1.110 |
Why?
| | Aged | 46 | 2022 | 18969 | 1.060 |
Why?
| | Middle Aged | 51 | 2022 | 26605 | 1.010 |
Why?
| | Adenocarcinoma | 7 | 2023 | 787 | 1.000 |
Why?
| | Endoscopic Ultrasound-Guided Fine Needle Aspiration | 7 | 2019 | 52 | 0.920 |
Why?
| | Retrospective Studies | 27 | 2023 | 12521 | 0.900 |
Why?
| | Duodenal Neoplasms | 1 | 2023 | 19 | 0.880 |
Why?
| | Common Bile Duct Neoplasms | 1 | 2023 | 24 | 0.880 |
Why?
| | Ampulla of Vater | 1 | 2023 | 30 | 0.870 |
Why?
| | Endoscopy | 3 | 2015 | 245 | 0.870 |
Why?
| | Choledochal Cyst | 2 | 2020 | 17 | 0.860 |
Why?
| | Adenocarcinoma, Mucinous | 2 | 2016 | 61 | 0.830 |
Why?
| | Humans | 91 | 2023 | 114043 | 0.820 |
Why?
| | Treatment Outcome | 25 | 2023 | 9049 | 0.820 |
Why?
| | Adenoma | 2 | 2023 | 187 | 0.810 |
Why?
| | Cholangitis | 1 | 2022 | 19 | 0.780 |
Why?
| | Laparoscopy | 3 | 2021 | 395 | 0.770 |
Why?
| | Male | 56 | 2023 | 55396 | 0.760 |
Why?
| | Pancreatectomy | 2 | 2021 | 167 | 0.760 |
Why?
| | Female | 58 | 2023 | 59325 | 0.750 |
Why?
| | Endoscopes, Gastrointestinal | 6 | 2013 | 12 | 0.740 |
Why?
| | Pancreatitis | 4 | 2021 | 105 | 0.720 |
Why?
| | Artificial Intelligence | 1 | 2022 | 144 | 0.720 |
Why?
| | Cytodiagnosis | 1 | 2020 | 29 | 0.690 |
Why?
| | Calcinosis | 2 | 2019 | 239 | 0.680 |
Why?
| | Intestine, Small | 2 | 2019 | 121 | 0.680 |
Why?
| | Liver Neoplasms | 1 | 2023 | 504 | 0.670 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2020 | 308 | 0.640 |
Why?
| | Lithotripsy, Laser | 2 | 2015 | 8 | 0.610 |
Why?
| | Adult | 33 | 2023 | 30375 | 0.590 |
Why?
| | Aneurysm, False | 1 | 2018 | 45 | 0.580 |
Why?
| | Catheterization | 7 | 2019 | 158 | 0.580 |
Why?
| | Disposable Equipment | 1 | 2017 | 15 | 0.570 |
Why?
| | Foreign Bodies | 1 | 2018 | 93 | 0.570 |
Why?
| | Laser Therapy | 1 | 2018 | 99 | 0.560 |
Why?
| | Aged, 80 and over | 16 | 2018 | 6306 | 0.530 |
Why?
| | Polyethylene | 1 | 2016 | 9 | 0.520 |
Why?
| | Biopsy | 6 | 2018 | 1024 | 0.520 |
Why?
| | Prospective Studies | 22 | 2023 | 6195 | 0.510 |
Why?
| | Gastroenterology | 4 | 2019 | 159 | 0.510 |
Why?
| | Gallbladder Diseases | 1 | 2015 | 6 | 0.500 |
Why?
| | Postoperative Complications | 3 | 2022 | 2122 | 0.500 |
Why?
| | Biomarkers, Tumor | 2 | 2014 | 1032 | 0.490 |
Why?
| | Pancreatic Juice | 1 | 2014 | 2 | 0.480 |
Why?
| | Learning Curve | 5 | 2019 | 63 | 0.470 |
Why?
| | Metals | 4 | 2023 | 105 | 0.460 |
Why?
| | CA-19-9 Antigen | 1 | 2014 | 14 | 0.460 |
Why?
| | Sensitivity and Specificity | 9 | 2021 | 1690 | 0.460 |
Why?
| | Sphincterotomy, Endoscopic | 4 | 2019 | 24 | 0.460 |
Why?
| | Hemorrhage | 1 | 2018 | 600 | 0.450 |
Why?
| | Gastrointestinal Diseases | 4 | 2022 | 182 | 0.430 |
Why?
| | Ultrasonography, Interventional | 3 | 2022 | 120 | 0.420 |
Why?
| | Cholestasis, Intrahepatic | 1 | 2013 | 39 | 0.420 |
Why?
| | Follow-Up Studies | 12 | 2021 | 4392 | 0.420 |
Why?
| | Predictive Value of Tests | 7 | 2017 | 1791 | 0.410 |
Why?
| | Pancreatitis, Acute Necrotizing | 2 | 2023 | 11 | 0.400 |
Why?
| | Clinical Competence | 5 | 2019 | 882 | 0.390 |
Why?
| | Liver Diseases | 1 | 2014 | 254 | 0.390 |
Why?
| | Anastomosis, Roux-en-Y | 2 | 2022 | 25 | 0.380 |
Why?
| | Biliary Tract Neoplasms | 3 | 2016 | 20 | 0.360 |
Why?
| | Young Adult | 8 | 2018 | 10444 | 0.320 |
Why?
| | Foreign-Body Migration | 2 | 2006 | 35 | 0.310 |
Why?
| | Natural Orifice Endoscopic Surgery | 3 | 2018 | 26 | 0.310 |
Why?
| | Gastrointestinal Hemorrhage | 2 | 2008 | 101 | 0.300 |
Why?
| | Pancreatic Cyst | 3 | 2018 | 46 | 0.300 |
Why?
| | Needles | 3 | 2019 | 49 | 0.300 |
Why?
| | Video Recording | 4 | 2016 | 141 | 0.300 |
Why?
| | B7-1 Antigen | 1 | 2008 | 53 | 0.300 |
Why?
| | Bile Ducts, Extrahepatic | 2 | 2020 | 24 | 0.280 |
Why?
| | Dilatation | 2 | 2018 | 58 | 0.280 |
Why?
| | Gallbladder | 2 | 2022 | 15 | 0.280 |
Why?
| | Abdominal Pain | 4 | 2023 | 134 | 0.270 |
Why?
| | Cholelithiasis | 3 | 2015 | 31 | 0.260 |
Why?
| | Hemostatic Techniques | 1 | 2005 | 37 | 0.240 |
Why?
| | Fluorouracil | 2 | 2020 | 152 | 0.240 |
Why?
| | Catheters | 2 | 2015 | 64 | 0.230 |
Why?
| | Ambulatory Care Facilities | 1 | 2006 | 212 | 0.230 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2008 | 445 | 0.230 |
Why?
| | Guanidines | 1 | 2023 | 33 | 0.220 |
Why?
| | Adolescent | 10 | 2018 | 17800 | 0.220 |
Why?
| | Esters | 1 | 2023 | 62 | 0.220 |
Why?
| | Quality of Life | 3 | 2023 | 2343 | 0.210 |
Why?
| | Cholecystitis, Acute | 1 | 2022 | 16 | 0.210 |
Why?
| | Prosthesis Implantation | 2 | 2019 | 138 | 0.210 |
Why?
| | Self Expandable Metallic Stents | 1 | 2022 | 14 | 0.200 |
Why?
| | Equipment Design | 8 | 2013 | 503 | 0.200 |
Why?
| | Pain | 3 | 2022 | 701 | 0.200 |
Why?
| | Plastics | 2 | 2022 | 36 | 0.200 |
Why?
| | Choledochostomy | 1 | 2022 | 11 | 0.200 |
Why?
| | Multicenter Studies as Topic | 1 | 2022 | 249 | 0.190 |
Why?
| | United States | 8 | 2017 | 12137 | 0.190 |
Why?
| | Multivariate Analysis | 3 | 2021 | 1422 | 0.190 |
Why?
| | Antimetabolites, Antineoplastic | 2 | 2020 | 80 | 0.190 |
Why?
| | Randomized Controlled Trials as Topic | 4 | 2022 | 1204 | 0.180 |
Why?
| | Tegafur | 1 | 2020 | 3 | 0.180 |
Why?
| | Oxonic Acid | 1 | 2020 | 3 | 0.180 |
Why?
| | Lasers | 1 | 2021 | 121 | 0.180 |
Why?
| | Logistic Models | 3 | 2021 | 1829 | 0.170 |
Why?
| | Dissection | 2 | 2018 | 51 | 0.170 |
Why?
| | ROC Curve | 2 | 2018 | 441 | 0.170 |
Why?
| | Living Donors | 1 | 2022 | 270 | 0.170 |
Why?
| | Hydrogen Peroxide | 1 | 2021 | 288 | 0.160 |
Why?
| | Fiducial Markers | 1 | 2019 | 8 | 0.160 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2004 | 577 | 0.160 |
Why?
| | Urinary Calculi | 1 | 2019 | 11 | 0.160 |
Why?
| | Carcinoembryonic Antigen | 2 | 2018 | 38 | 0.160 |
Why?
| | Radiotherapy, Image-Guided | 1 | 2019 | 30 | 0.160 |
Why?
| | Anastomosis, Surgical | 1 | 2019 | 135 | 0.160 |
Why?
| | Reproducibility of Results | 3 | 2019 | 2764 | 0.150 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2023 | 850 | 0.150 |
Why?
| | Lasers, Solid-State | 1 | 2018 | 21 | 0.150 |
Why?
| | Journal Impact Factor | 1 | 2018 | 27 | 0.150 |
Why?
| | Cystadenoma, Serous | 1 | 2018 | 17 | 0.150 |
Why?
| | Feasibility Studies | 4 | 2018 | 735 | 0.150 |
Why?
| | Cholecystectomy, Laparoscopic | 1 | 2018 | 46 | 0.150 |
Why?
| | Fiber Optic Technology | 2 | 2015 | 18 | 0.150 |
Why?
| | Education, Medical, Graduate | 2 | 2019 | 366 | 0.150 |
Why?
| | Hospitals, University | 1 | 2018 | 169 | 0.140 |
Why?
| | Diagnosis, Differential | 3 | 2015 | 1331 | 0.140 |
Why?
| | Gastrointestinal Neoplasms | 2 | 2008 | 59 | 0.140 |
Why?
| | Reoperation | 1 | 2019 | 513 | 0.140 |
Why?
| | Time Factors | 3 | 2019 | 6077 | 0.140 |
Why?
| | Narrow Band Imaging | 1 | 2016 | 14 | 0.140 |
Why?
| | Neuroendocrine Tumors | 1 | 2018 | 85 | 0.140 |
Why?
| | Regression Analysis | 1 | 2018 | 945 | 0.130 |
Why?
| | Risk Factors | 4 | 2021 | 8614 | 0.130 |
Why?
| | Fellowships and Scholarships | 1 | 2019 | 224 | 0.130 |
Why?
| | Neoplasms, Cystic, Mucinous, and Serous | 1 | 2016 | 25 | 0.130 |
Why?
| | Periodicals as Topic | 1 | 2018 | 180 | 0.130 |
Why?
| | Cystadenoma, Mucinous | 1 | 2015 | 13 | 0.120 |
Why?
| | Pathology, Clinical | 1 | 2015 | 32 | 0.120 |
Why?
| | Cystadenocarcinoma, Mucinous | 1 | 2015 | 14 | 0.120 |
Why?
| | Radio Waves | 1 | 2015 | 16 | 0.120 |
Why?
| | Single-Blind Method | 1 | 2016 | 259 | 0.120 |
Why?
| | Pancreaticoduodenectomy | 1 | 2016 | 132 | 0.120 |
Why?
| | Length of Stay | 1 | 2019 | 957 | 0.120 |
Why?
| | Neoplasm Staging | 5 | 2009 | 1162 | 0.110 |
Why?
| | Tertiary Care Centers | 1 | 2014 | 126 | 0.110 |
Why?
| | Europe | 1 | 2014 | 332 | 0.110 |
Why?
| | Fluoroscopy | 3 | 2019 | 139 | 0.110 |
Why?
| | Databases, Factual | 1 | 2018 | 1125 | 0.110 |
Why?
| | Double-Balloon Enteroscopy | 1 | 2013 | 1 | 0.110 |
Why?
| | Referral and Consultation | 2 | 2016 | 632 | 0.100 |
Why?
| | Cohort Studies | 2 | 2014 | 4883 | 0.100 |
Why?
| | Child | 4 | 2018 | 18400 | 0.100 |
Why?
| | Esophageal Neoplasms | 2 | 2005 | 270 | 0.100 |
Why?
| | Catheter Ablation | 1 | 2015 | 287 | 0.100 |
Why?
| | Incidence | 1 | 2018 | 2314 | 0.100 |
Why?
| | Cyst Fluid | 2 | 2018 | 27 | 0.100 |
Why?
| | Technology Assessment, Biomedical | 2 | 2008 | 29 | 0.090 |
Why?
| | Antibiotic Prophylaxis | 1 | 2012 | 95 | 0.090 |
Why?
| | Practice Guidelines as Topic | 1 | 2018 | 1381 | 0.090 |
Why?
| | Biopsy, Fine-Needle | 2 | 2008 | 65 | 0.090 |
Why?
| | Radiography | 1 | 2013 | 803 | 0.090 |
Why?
| | Palliative Care | 2 | 2009 | 641 | 0.090 |
Why?
| | Minimally Invasive Surgical Procedures | 2 | 2008 | 154 | 0.090 |
Why?
| | Colorado | 2 | 2018 | 4090 | 0.090 |
Why?
| | Prognosis | 3 | 2016 | 3315 | 0.080 |
Why?
| | Risk Assessment | 4 | 2016 | 2958 | 0.080 |
Why?
| | Abdominal Abscess | 1 | 2009 | 25 | 0.080 |
Why?
| | Intestinal Perforation | 1 | 2008 | 39 | 0.080 |
Why?
| | Decompression, Surgical | 1 | 2009 | 92 | 0.080 |
Why?
| | Duodenum | 1 | 2008 | 62 | 0.080 |
Why?
| | Gastric Mucosa | 1 | 2008 | 46 | 0.080 |
Why?
| | V-Set Domain-Containing T-Cell Activation Inhibitor 1 | 1 | 2008 | 10 | 0.080 |
Why?
| | Tissue Fixation | 1 | 2008 | 27 | 0.080 |
Why?
| | Balloon Occlusion | 1 | 2008 | 23 | 0.070 |
Why?
| | NAD(P)H Dehydrogenase (Quinone) | 1 | 2008 | 31 | 0.070 |
Why?
| | Analgesics, Opioid | 1 | 2015 | 771 | 0.070 |
Why?
| | Wounds, Penetrating | 1 | 2008 | 68 | 0.070 |
Why?
| | Equipment Safety | 4 | 2008 | 40 | 0.070 |
Why?
| | Immunoenzyme Techniques | 1 | 2008 | 192 | 0.070 |
Why?
| | Deoxycytidine | 1 | 2008 | 138 | 0.070 |
Why?
| | Rectal Neoplasms | 1 | 2008 | 122 | 0.070 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2008 | 124 | 0.070 |
Why?
| | Image Enhancement | 1 | 2008 | 158 | 0.070 |
Why?
| | Tomography, X-Ray Computed | 2 | 2014 | 2272 | 0.070 |
Why?
| | Academic Medical Centers | 1 | 2009 | 405 | 0.070 |
Why?
| | Prosthesis Design | 2 | 2009 | 283 | 0.070 |
Why?
| | Duodenoscopy | 1 | 2006 | 7 | 0.070 |
Why?
| | Laser Coagulation | 1 | 2006 | 53 | 0.070 |
Why?
| | Anesthesia, General | 1 | 2006 | 44 | 0.070 |
Why?
| | Conscious Sedation | 1 | 2006 | 78 | 0.060 |
Why?
| | Acute Disease | 1 | 2008 | 907 | 0.060 |
Why?
| | Pain Management | 1 | 2008 | 285 | 0.060 |
Why?
| | Thoracic Neoplasms | 1 | 2005 | 31 | 0.060 |
Why?
| | Infant | 1 | 2018 | 7943 | 0.060 |
Why?
| | Equipment Failure | 1 | 2005 | 107 | 0.060 |
Why?
| | Growth Substances | 1 | 2004 | 138 | 0.060 |
Why?
| | Child, Preschool | 1 | 2018 | 9114 | 0.060 |
Why?
| | Liver Cirrhosis | 1 | 2006 | 227 | 0.060 |
Why?
| | Intestinal Mucosa | 1 | 2008 | 532 | 0.050 |
Why?
| | Pilot Projects | 1 | 2008 | 1360 | 0.050 |
Why?
| | Diagnostic Tests, Routine | 1 | 2003 | 87 | 0.050 |
Why?
| | Necrosis | 1 | 2023 | 209 | 0.050 |
Why?
| | Severity of Illness Index | 1 | 2009 | 2537 | 0.050 |
Why?
| | Polycystic Kidney, Autosomal Dominant | 1 | 2004 | 209 | 0.050 |
Why?
| | Anti-Infective Agents, Local | 1 | 2021 | 39 | 0.050 |
Why?
| | Double-Blind Method | 1 | 2023 | 1656 | 0.040 |
Why?
| | Drug Combinations | 1 | 2020 | 286 | 0.040 |
Why?
| | Myotomy | 1 | 2018 | 8 | 0.040 |
Why?
| | Endoscopic Mucosal Resection | 1 | 2018 | 20 | 0.040 |
Why?
| | Equipment Contamination | 1 | 2018 | 54 | 0.040 |
Why?
| | Administration, Oral | 1 | 2020 | 725 | 0.040 |
Why?
| | Republic of Korea | 1 | 2017 | 27 | 0.040 |
Why?
| | Surgical Instruments | 1 | 2018 | 48 | 0.040 |
Why?
| | Hospitalization | 1 | 2006 | 1762 | 0.040 |
Why?
| | Surgery, Computer-Assisted | 1 | 2018 | 61 | 0.040 |
Why?
| | Bile | 2 | 2009 | 26 | 0.040 |
Why?
| | Colonic Polyps | 1 | 2018 | 67 | 0.030 |
Why?
| | United Kingdom | 1 | 2017 | 226 | 0.030 |
Why?
| | Cytokines | 1 | 2004 | 1824 | 0.030 |
Why?
| | Disinfection | 1 | 2018 | 107 | 0.030 |
Why?
| | Prosthesis Failure | 2 | 2009 | 114 | 0.030 |
Why?
| | Liver | 1 | 2004 | 1633 | 0.030 |
Why?
| | Surveys and Questionnaires | 1 | 2008 | 4595 | 0.030 |
Why?
| | Radiotherapy, Adjuvant | 2 | 2008 | 182 | 0.030 |
Why?
| | Videotape Recording | 1 | 2016 | 30 | 0.030 |
Why?
| | Colonoscopy | 1 | 2018 | 197 | 0.030 |
Why?
| | Barrett Esophagus | 1 | 2018 | 143 | 0.030 |
Why?
| | Gastroenterologists | 1 | 2016 | 18 | 0.030 |
Why?
| | Radiologists | 1 | 2016 | 35 | 0.030 |
Why?
| | Quality Indicators, Health Care | 1 | 2018 | 285 | 0.030 |
Why?
| | Chemotherapy, Adjuvant | 2 | 2008 | 332 | 0.030 |
Why?
| | Watchful Waiting | 1 | 2016 | 54 | 0.030 |
Why?
| | Phantoms, Imaging | 1 | 2016 | 123 | 0.030 |
Why?
| | Societies, Medical | 2 | 2008 | 655 | 0.030 |
Why?
| | Disease Management | 1 | 2018 | 556 | 0.030 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2018 | 284 | 0.030 |
Why?
| | Odds Ratio | 1 | 2016 | 951 | 0.030 |
Why?
| | Program Evaluation | 1 | 2017 | 820 | 0.030 |
Why?
| | Combined Modality Therapy | 2 | 2005 | 1117 | 0.020 |
Why?
| | Colorectal Neoplasms | 1 | 2018 | 592 | 0.020 |
Why?
| | False Negative Reactions | 1 | 2011 | 48 | 0.020 |
Why?
| | False Positive Reactions | 1 | 2011 | 109 | 0.020 |
Why?
| | Stainless Steel | 1 | 2009 | 21 | 0.020 |
Why?
| | Hematoma | 1 | 2009 | 50 | 0.020 |
Why?
| | Alloys | 1 | 2009 | 30 | 0.020 |
Why?
| | Observer Variation | 1 | 2010 | 298 | 0.020 |
Why?
| | Terminally Ill | 1 | 2009 | 33 | 0.020 |
Why?
| | International Cooperation | 1 | 2009 | 169 | 0.020 |
Why?
| | Medical Laboratory Science | 1 | 2008 | 7 | 0.020 |
Why?
| | Rupture | 1 | 2008 | 96 | 0.020 |
Why?
| | Ligation | 1 | 2008 | 75 | 0.020 |
Why?
| | Miniaturization | 1 | 2008 | 23 | 0.020 |
Why?
| | Premedication | 1 | 2008 | 36 | 0.020 |
Why?
| | Probability | 1 | 2009 | 286 | 0.020 |
Why?
| | Capecitabine | 1 | 2008 | 45 | 0.020 |
Why?
| | Evaluation Studies as Topic | 1 | 2008 | 167 | 0.020 |
Why?
| | Esophageal and Gastric Varices | 1 | 2008 | 30 | 0.020 |
Why?
| | Total Quality Management | 1 | 2008 | 61 | 0.020 |
Why?
| | Radiotherapy Dosage | 1 | 2008 | 243 | 0.020 |
Why?
| | Morbidity | 1 | 2008 | 277 | 0.020 |
Why?
| | Remission Induction | 1 | 2008 | 233 | 0.020 |
Why?
| | Safety Management | 1 | 2008 | 106 | 0.020 |
Why?
| | Diarrhea | 1 | 2008 | 170 | 0.020 |
Why?
| | Biopsy, Needle | 1 | 2007 | 180 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2009 | 813 | 0.020 |
Why?
| | Costs and Cost Analysis | 1 | 2007 | 196 | 0.020 |
Why?
| | Disease-Free Survival | 1 | 2008 | 618 | 0.020 |
Why?
| | Survival Analysis | 1 | 2009 | 1206 | 0.020 |
Why?
| | Obesity | 1 | 2018 | 2505 | 0.020 |
Why?
| | Safety | 1 | 2007 | 298 | 0.020 |
Why?
| | Patient Selection | 1 | 2009 | 629 | 0.020 |
Why?
| | Prostheses and Implants | 1 | 2006 | 135 | 0.010 |
Why?
| | Receptors, Interleukin-8B | 1 | 2004 | 22 | 0.010 |
Why?
| | Survival Rate | 1 | 2008 | 1638 | 0.010 |
Why?
| | Recurrence | 1 | 2007 | 925 | 0.010 |
Why?
| | Esophagectomy | 1 | 2005 | 110 | 0.010 |
Why?
| | Swine | 1 | 2006 | 687 | 0.010 |
Why?
| | Positron-Emission Tomography | 1 | 2005 | 260 | 0.010 |
Why?
| | Ischemia | 1 | 2004 | 361 | 0.010 |
Why?
| | Epithelial Cells | 1 | 2004 | 946 | 0.010 |
Why?
| | Biomarkers | 1 | 2008 | 3397 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2006 | 3498 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2004 | 3861 | 0.010 |
Why?
| | Animals | 1 | 2006 | 31565 | 0.000 |
Why?
|
|
Shah's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|